PAR 2.17% 23.5¢ paradigm biopharmaceuticals limited..

Ann: Successful MPSVI Safety Review and PARA OA 008 Update, page-27

  1. 1,316 Posts.
    lightbulb Created with Sketch. 263
    A fairly extensive equine study that was published in the Journal of Arthritis concluded with the following...

    Conclusions: NaPPS resulted in signifcant improvement in clinical signs and articular cartilage healing, and no adverse effects were detected confrming that NaPPS has disease-modifying properties.

    The full study, along with medical imaging, can be found online. I will copy and paste the link in another post. Well worth a read.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.